Accelerating Science: The people and technologies changing the world >

Miniaturized high-throughput transcriptomics for preclinical drug discovery
23 Jun 2023

Biopharmaceutical companies utilize high-throughput drug screens to understand targets of regulators in biological processes and to identify new pre-clinical lead molecules. Screening through high-throughput transcriptomic profiling enables a global view of gene regulation in a model-agnostic format. Utilizing DRUG-Seq to generate large-scale RNA sequencing data may accelerate pharmacological profiling of the compound library (e.g., mechanisms of action, and off-target profiling).

Miniaturizing drug screening helps to accelerate throughput while simultaneously reducing costs. In this webinar, Ian Shoemaker and Kelly Parliament from Beckman Coulter Life Sciences will share how the Echo® 655T instrument, an acoustic liquid handler, allows for miniaturization of the drug screen process through the rapid and accurate transfer of compounds at volumes as low as 2.5 nL without the use of plastic tips.

They will also explain how bulk RNA barcoding and sequencing (BRB-seq) enables the use of high-throughput RNA library preparation and sequencing by drastically reducing price and preparation time through the utilization of RNA barcoding and multiplexed library preparation. BRB-seq prepares 3’ RNA sequencing libraries suited for differential gene expression analysis. Explore how the MERCURIUS™ Cell Lysate BRB-seq Library Preparation kit enables the use of crude cell lysates directly in reverse transcription steps, thus saving cost and time. The entire automated BRB-seq workflow from cell lysis to sequencing-ready DNA libraries can be completed in seven hours for 96 or 384 samples on the Biomek i7 dual hybrid workstation.

Key learning objectives

  • Discover how DRUG-Seq can be used to generate large-scale RNA sequencing data that may accelerate pharmacological profiling of the compound library
  • Learn about the combined DRUG-Seq workflow of miniatured high-throughput drug screening and transcriptomics using the Echo 655T acoustic liquid handler and the Biomek i7 Automated Workstation

Who should attend?

  • Lab directors and managers in preclinical drug screening and next-generation sequencing
  • Research professionals interested in transcriptomic profiling and automation

Certificate of attendance

webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

Beckman Coulter Life Sciences